WEBULL
WebtradeDownload

Does Narrowed Guidance Change The Bull Case For Inspire Medical Systems Stock (INSP)?

Simply Wall St · 2d ago
  • Inspire Medical Systems reported third quarter 2026 sales of US$206.7 million and a net loss of US$24.39 million, along with narrowed full year revenue guidance of US$850 million to US$860 million and projected diluted EPS between a loss of US$0.36 and US$0.10.
  • The shift from prior year profitability to current losses, together with reduced sales for both the quarter and year to date, highlights rising execution and cost pressures as Inspire Medical Systems prepares to present at the Stifel 2026 Healthcare Conference.
  • We will examine how Inspire Medical Systems' investment narrative is affected by weaker earnings and tighter full year guidance.

Scan beyond Inspire Medical Systems and compare these tightening guidance and loss-making conditions to peers with stronger trends using the hand picked list of solid balance sheet and fundamentals (24 results).

Inspire Medical Systems Investment Narrative Recap

To own Inspire Medical Systems, you need to believe the obstructive sleep apnea opportunity, the Inspire V platform and the digital tools around it can support a durable procedure franchise once current issues ease. The latest quarter, with lower sales and a swing to losses, tests that belief because it points to operational friction and higher costs in the near term.

The analyst consensus Narrative on Simply Wall St leans heavily on reimbursement normalization, coding clarity and a smoother Inspire V rollout as key supports for the story. With guidance now tighter and still pointing to a full year loss, the near term catalyst is cleaner execution on volumes and coding. The biggest immediate risk is that WISeR disruption, coding education and legal scrutiny keep weighing on revenue and margins longer than expected.

The narrowed 2026 revenue and diluted EPS outlook is the announcement that really matters here. Management now expects US$850 million to US$860 million of sales and diluted EPS between a loss of US$0.36 and US$0.10. That range still embeds pressure from coding and WISeR related disruption that previously cut about US$40 million from Q2 revenue and is expected to affect the year by US$120 million to US$130 million.

For you as an investor, that guidance update sets a clearer hurdle for upcoming catalysts like reimbursement adjustments, Inspire V procedure trends and any operational updates around SleepSync, Inspire Connect and Project Horizon. It also frames risk more sharply, since extended reimbursement friction or further coding changes, especially around CPT 64582 physician payments, could keep procedure economics under strain and limit how quickly Inspire Medical Systems can move back toward profitability already reflected in consensus expectations.

Inspire Medical Systems' current analyst narrative points to revenues of US$983.3 million and earnings of US$76.9 million by 2029. That outlook assumes revenue grows at 3.0% per year and earnings decline by US$58.1 million from US$135.0 million today.

Uncover how Inspire Medical Systems' fair value indicates a 9% potential upside to its current price that may not last much longer.

NYSE:INSP 1-Year Stock Price Chart
NYSE:INSP 1-Year Stock Price Chart

Exploring Other Perspectives

One bearish angle on Inspire Medical Systems focuses on competition rather than coding. The most pessimistic analysts worry that GLP 1 therapies and at-home digital sleep tools could cap long-term demand. Even so, they were still modeling about US$939.5 million of revenue and only US$26.4 million of earnings by 2029 before this earnings miss and the upcoming Stifel conference, which could both nudge those views further.

Explore 3 other Inspire Medical Systems fair value estimates, including one that suggests there could be as much as 28% downside from the current price.

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Looking for more investment ideas beyond Inspire Medical Systems?

If Inspire Medical Systems has sharpened your thinking about risk, balance sheets and earnings quality, it can be useful to line those questions up against a broader watchlist. The Simply Wall St Screener lets you quickly filter for different types of opportunities so you can compare narrative, financial strength and valuation style side by side.